ARS Pharmaceuticals, Inc Total Liabilities
ARS Pharmaceuticals, Inc total liabilities. Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has total liabilities worth $213.39 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ARS Pharmaceuticals, Inc (SPRY) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ARS Pharmaceuticals, Inc (2018–2025)
Total liabilities of ARS Pharmaceuticals, Inc from 2018 to 2025. This chart illustrates how ARS Pharmaceuticals, Inc's total liabilities have evolved over time, based on quarterly financial data.
ARS Pharmaceuticals, Inc Competitors by Total Liabilities
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KNEAT.COM INC.
F:FOBK
|
Germany | €56.74 Million |
|
Qingdao Richmat Intelligence Technology Co. Ltd. A
SHE:301320
|
China | CN¥514.45 Million |
|
Schweizerische Nationalbank
SW:SNBN
|
Switzerland | CHF724.25 Billion |
|
FVCBankcorp Inc
NASDAQ:FVCB
|
USA | $2.10 Billion |
|
NN Inc
NASDAQ:NNBR
|
USA | $305.28 Million |
|
Insyde Software
TWO:6231
|
Taiwan | NT$496.30 Million |
|
Chin Hin Group Property Bhd
KLSE:7187
|
Malaysia | RM990.06 Million |
|
Guolin Environmental Tech Co Ltd
SHE:300786
|
China | CN¥658.63 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down ARS Pharmaceuticals, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ARS Pharmaceuticals, Inc total assets.
Liquidity & Leverage Metrics
ARS Pharmaceuticals, Inc Total Liabilities Ratios Explained
ARS Pharmaceuticals, Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ARS Pharmaceuticals, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ARS Pharmaceuticals, Inc (2018–2025)
The table below shows the annual total liabilities of ARS Pharmaceuticals, Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $213.39 Million | +126.16% |
| 2024-12-31 | $94.36 Million | +3786.12% |
| 2023-12-31 | $2.43 Million | -71.60% |
| 2022-12-31 | $8.55 Million | -90.78% |
| 2021-12-31 | $92.72 Million | +129.16% |
| 2020-12-31 | $40.46 Million | +90.40% |
| 2019-12-31 | $21.25 Million | +127.27% |
| 2018-12-31 | $9.35 Million | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more